Monsalve 2017 Abstract MITOEAGLE Barcelona: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Abstract | {{Abstract | ||
|title=[[File:MITOEAGLE-representation.jpg|left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | |title=[[File:MITOEAGLE-representation.jpg|left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | ||
Mitochondrial biogenesis in PMBC: potential biomarkers | Mitochondrial biogenesis in PMBC: potential biomarkers. | ||
|info=[[MITOEAGLE]] | |info=[[MITOEAGLE]] | ||
|authors=Fabregat-Andres O, Ridocci-Soriano F, Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, M, Monsalve M | |authors=Fabregat-Andres O, Ridocci-Soriano F, Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, M, Monsalve M | ||
| Line 14: | Line 14: | ||
Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI. | Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI. | ||
|editor=[[Kandolf G]], | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=mt-Biogenesis;mt-density | |area=mt-Biogenesis;mt-density, mt-Medicine, Patients, Pharmacology;toxicology | ||
|injuries=Ischemia-reperfusion | |||
|tissues=Blood cells | |tissues=Blood cells | ||
|event=A4 | |event=A4 | ||
Revision as of 10:53, 3 March 2017
 Mitochondrial biogenesis in PMBC: potential biomarkers. |
Link: MITOEAGLE
Fabregat-Andres O, Ridocci-Soriano F, Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, M, Monsalve M (2017)
Event: MITOEAGLE Barcelona 2017
Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI.
We prospectively studied 31 patients with a first anterior STEMI successfully reperfused. We analyzed PGC-1a mRNA in blood samples on admission and 72 h later, and tested its correlation with the extent of initial myocardial damage and cardiac volume and function at 6 months. Myocardial edema and necrosis were assessed during the first week by cardiac magnetic resonance (CMR). A second CMR examination was performed at 6 months to evaluate scar burden and AVR, defined as an increase over 10% in left ventricular end-diastolic volume (LVEDV).
PGC-1a induction is associated with larger edemas and higher risk of AVR. Patients with high basal PGC-1a levels have larger areas of initial salvaged myocardium (SM) and SM at 6 months. In the absence of microvascular obstruction (MVO) and with high basal PGC-1a, the risk of AVR is lower than in the presence of MVO with low basal PGC-1a.
Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI.
• Bioblast editor: Kandolf G
Labels: MiParea: mt-Biogenesis;mt-density, mt-Medicine, Patients, Pharmacology;toxicology
Stress:Ischemia-reperfusion
Tissue;cell: Blood cells
Event: A4
PMBCs
Affiliations
- Consorcio Hospital General Univ Valencia, Inst Investigaciones Biomédicas “Alberto Sols” (CSIC), Madrid; Spain.
